Trial Profile
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Active Ankylosing Spondylitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 May 2020
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Ankylosing spondylitis
- Focus Registrational; Therapeutic Use
- Acronyms POSTURE
- Sponsors Amgen; Celgene Corporation
- 10 Jun 2019 Status changed from active, no longer recruiting to completed.
- 02 May 2019 This trial was completed in Netherlands (end date: 2018-10-25), according to European Clinical Trials Database.
- 20 Feb 2019 This trial was completed in Slovakia (end date: 2018-10-25), according to European Clinical Trials Database.